menu
    • menu
    [{"orgOrder":0,"company":"AnHorn Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AH 001","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"AnHorn Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHorn Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHorn Medicines \/ Undisclosed"},{"orgOrder":0,"company":"AnHorn Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AH 001","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"AnHorn Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHorn Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHorn Medicines \/ Undisclosed"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TWi Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Src kinase||Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Athenex","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ Athenex"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AnHorn Medicines

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            AnHorn Medicines

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AH 001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple As...

                            Details : AH-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alopecia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : AH 001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AnHorn Medicines

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            AnHorn Medicines

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AH 001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AnHorn Doses First Patient in AH-001 Phase I Trial in U.S.

                            Details : AH-001 is a first-in-class protein degrader, which is currrently being evaluated for the treatment of androgenetic alopecia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 26, 2025

                            Lead Product(s) : AH 001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oneness Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oneness Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB825

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Heal...

                            Details : FB825 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 19, 2023

                            Lead Product(s) : FB825

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PharmaEssentia

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PharmaEssentia

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Athenex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis

                            Details : KX01 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 31, 2022

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Athenex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TWi Biotechnology

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TWi Biotechnology

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tofacitinib Citrate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TWiB Receives Canada Health Approval for AC-1101 Phase 1 CTA

                            Details : Health Canada has approved Ancheng Biotech's open-label, fixed-sequence, two-period, comparative bioavailability study of AC-1101 (Tofacitinib Citrate). Tofacitinib Citrate is a topical JAK inhibitor for the treatment of vitiligo.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2020

                            Lead Product(s) : Tofacitinib Citrate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth